L-DOPA在白天波动性 dystonia:两个不同的临床表现,一个治疗
Beyza Karataş1, Ayten Güleç2, Ömer YiğitSezer1,3
1Department of Pediatrics, Division of Pediatric Neurology, Faculty of Medicine, Erciyes University, Kayseri, Turkey.
Neurogenetics
|December 2, 2025
概括
在儿童中,可有效治疗多巴反应性 dystonia (DRD). 即使在基因确认之前,早期的L-DOPA治疗也可以显著改善疑似DRD病例的运动功能和神经发育.
科学领域:
- 神经学 神经学
- 儿科 儿科 儿科
- 遗传学 遗传学 是一个
背景情况:
- 多巴反应性 dystonia (DRD) 是一种罕见的儿科疾病.
- 早期诊断和干预对于最佳结果至关重要.
- 通过L-DOPA治疗,可以有效地管理DRD.
研究的目的:
- 报告了两个不同的儿科DRD病例,最初被误诊为脑.
- 强调在白天波动的情况下考虑DRD的重要性.
- 倡导早期L-DOPA试验作为诊断和治疗工具.
主要方法:
- 两名儿科患者的病例报告,诊断错误的 dystonia.
- 临床观察运动症状的日间波动.
- 对低剂量利沃多巴 (L-DOPA) 的治疗反应的评估.
主要成果:
- 两位患者都出现了白天波动性心肌,最初诊断错误.
- 迅速启动低剂量L-DOPA导致显著的精神运动和神经系统改善.
- L-DOPA治疗对日常和重要功能产生了积极影响.
结论:
- 对L-DOPA的早期实证试验可以成为怀疑DRD的有价值的诊断方法.
- 这种策略可以在等待漫长的基因测试时提供重要的功能支持.
- 治疗第一的诊断方法在特定的儿科神经疾病中可能是有益的,如DRD.
相关概念视频
Parkinson's Disease: Treatment
945
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
945
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.5K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.5K
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
1.1K
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
1.1K
Drug Therapy
232
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
232


